Maternally derived recombinant human anti-hantavirus monoclonal antibodies are transferred to mouse offspring during lactation and neutralize virus in vitro

Journal of Virology

Volumn 80, Issue 8, 2006, Pages 4183-4186

  Yu, Shuyang ^a   Liang, Mifang ^b   Fan, BaoLiang ^c   Xu, Hongtao ^a   Li, Chuan ^b   Zhang, Quanfu ^b   Li, Dexin ^b   Tang, Bo ^a   Li, Shijie ^a   Dai, Yunping ^a   Wang, Meili ^a   Zheng, Min ^a   Yan, Bingxue ^a   Zhu, Qinghong ^a   Li, Ning ^a,d  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b China CDC   (China)

^c He Bei Agricultural University ^*  (China)

^d State Key Laboratories for Agrobiotechnology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT HUMAN MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST MILK; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; HANTAVIRUS; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; LACTATION; MALE; MOUSE; NEWBORN; NONHUMAN; PASSIVE IMMUNIZATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGENY; SERUM; SOUTHERN BLOTTING; SUCKLING; TRANSGENIC MOUSE; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HANTAVIRUS; IMMUNITY, MATERNALLY-ACQUIRED; LACTATION; MICE; MICE, TRANSGENIC; MILK; RECOMBINANT PROTEINS;

HANTAVIRUS; MUS MUSCULUS;

EID: 33645778556     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.80.8.4183-4186.2006     Document Type: Article

References (29)

1. Arikawa, J., A. L. Schmaljohn, J. M. Dalrymple, and C. S. Schmaljohn. 1989. Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies. J. Gen. Virol. 70(Pt. 3):615-624.
2. Arikawa, J., J. S. Yao, K. Yoshimatsu, I. Takashima, and N. Hashimoto. 1992. Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies. Arch. Virol. 126:271-281.
3. Casadevall, A., and L. A. Pirofski. 2004. New concepts in antibody-mediated immunity. Infect. Immun. 72:6191-6196.
4. Castilla, J., B. Pintado, I. Sola, J. M. Sanchez-Morgado, and L. Enjuanes. 1998. Engineering passive immunity in transgenic mice secreting virus-neutralizing antibodies in milk. Nat. Biotechnol. 16:349-354.
5. Cho, H. W., and C. R. Howard. 1999. Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax). Vaccine 17:2569-2575.
6. Custer, D. M., E. Thompson, C. S. Schmaljohn, T. G. Ksiazek, and J. W. Hooper. 2003. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J. Virol. 77:9894-9905.
7. Gavin, W. G., P. D. Pollock, D. Fell, C. Yelton, M. Cammuso, J. Harrington, P. Lewis-Williams, A. Midura, T. E. Oliver, B. Smith, Y. Wilburn, and A. H. M. Echelard. 1997. Expression of the antibody hBR96-2 in the milk of transgenic mice and production of hBR96-2 transgenic goats. Theriogenology 47:214.
8. Hjelle, B., S. A. Jenison, D. E. Goade, W. B. Green, R. M. Feddersen, and A. A. Scott 1995. Hantaviruses: clinical, microbiologic, and epidemiologic aspects. Crit. Rev. Clin. Lab. Sci. 32:469-508.
9. Hooper, J. W., K. I. Kamrud, F. Elgh, D. Custer, and C. S. Schmaljohn. 1999. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against Seoul virus infection. Virology 255:269-278.
10. Houdebine, L. M. 2002. Antibody manufacture in transgenic animals and comparisons with other systems. Curr. Opin. Biotechnol. 13:625-629.
11. Humphreys, D. P., and D. J. Glover. 2001. Therapeutic antibody production technologies: molecules, applications, expression and purification. Curr. Opin. Drug Discov. Dev. 4:172-185.
12. Koch, J., M. Liang, I. Queitsch, A. A. Kraus, and E. K. Bautz. 2003. Human recombinant neutralizing antibodies against Hantaan virus G2 protein. Virology 308:64-73.
13. Kolb, A. F., L. Pewe, J. Webster, S. Perlman, C. B. Whitelaw, and S. G. Siddell. 2001. Virus-neutralizing monoclonal antibody expressed in milk of transgenic mice provides full protection against virus-induced encephalitis. J. Virol. 75:2803-2809.
14. Koletzki, D., R. Schirmbeck, A. Lundkvist, H. Meisel, D. H. Kruger, and R. Ulrich. 2001. DNA vaccination of mice with a plasmid encoding Puumala hantavirus nucleocapsid protein mimics the B-cell response induced by virus infection. J. Biotechnol. 84:73-78.
15. Liang, M., M. Mahler, J. Koch, Y. Ji, D. Li, C. Schmaljohn, and E. K. Bautz. 2003. Generation of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain. J. Med. Virol. 69:99-107.
16. Limonta, J., A. Pedraza, A. Rodriguez, F. M. Freyre, A. M. Barral, F. O. Castro, R. Lleonart, C. A. Gracia, J. V. Gavilondo, and J. de la Fuente. 1995. Production of active anti-CD6 mouse/human chimeric antibodies in the milk of transgenic mice. Immunotechnology 1:107-113.
17. Maes, P., J. Clement, I. Gavrilovskaya, and M. Van Ranst. 2004. Hantaviruses: immunology, treatment, and prevention. Viral Immunol. 17:481-497.
18. McClain, D. J., P. L. Summers, S. A. Harrison, A. L. Schmaljohn, and C. S. Schmaljohn. 2000. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J. Med. Virol. 60:77-85.
19. Nakamura, T., R. Yanagihara, C. J. Gibbs, Jr., H. L. Amyx, and D. C. Gajdusek. 1985. Differential susceptibility and resistance of immunocompetent and immunodeficient mice to fatal Hantaan virus infection. Arch. Virol. 86:109-120.
20. Netski, D., B. H. Thran, and S. C. St. Jeor. 1999. Sin Nombre virus pathogenesis in Peromyscus maniculatus. J. Virol. 73:585-591.
21. Newton, D. L., D. Pollock, P. DiTullio, Y. Echelard, M. Harvey, B. Wilburn, J. Williams, H. R. Hoogenboom, J. C. Raus, H. M. Meade, and S. M. Rybak. 1999. Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice. J. Immunol. Methods 231:159-167.
22. Peters, C. J., G. L. Simpson, and H. Levy. 1999. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu. Rev. Med. 50:531-545.
23. Schmaljohn, C. S., Y. K. Chu, A. L. Schmaljohn, and J. M. Dalrymple. 1990. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J. Virol. 64:3162-3170.
24. Schmaljohn, C. S., and J. M. Dalrymple. 1983. Analysis of Hantaan virus RNA: evidence for a new genus of Bunyaviridae. Virology 131:482-491.
25. Sola, I., J. Castilla, B. Pintado, J. M. Sanchez-Morgado, C. B. Whitelaw, A. J. Clark, and L. Enjuanes. 1998. Transgenic mice secreting coronavirus neutralizing antibodies into the milk. J. Virol. 72:3762-3772.
26. Song, G. 1999. Epidemiological progresses of hemorrhagic fever with renal syndrome in China. Chin. Med. J. (Engl. Ed.) 112:472-477.
27. van Kuik-Romeijn, P., N. de Groot, E. Hooijberg, and H. A. de Boer. 2000. Expression of a functional mouse-human chimeric anti-CD19 antibody in the milk of transgenic mice. Transgenic Res. 9:155-159.
28. Yamanishi, K., O. Tanishita, M. Tamura, H. Asada, K. Kondo, M. Takagi, I. Yoshida, T. Konobe, and K. Fukai. 1988. Development of inactivated vaccine against virus causing haemorrhagic fever with renal syndrome. Vaccine 6:278-282.
29. Yanagihara, R., H. L. Amyx, and D. C. Gajdusek. 1985. Experimental infection with Puumala virus, the etiologic agent of nephropathia epidemica, in bank voles (Clethrionomys glareolus). J. Virol. 55:34-38.